Gene expression signature of hyperprogressive disease (HPD) in patients after anti-PD-1 immunotherapy
US12380963B2 · kind B2 · utility
0Cited by
11References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 14, 2020 |
| Grant date | Aug 5, 2025 |
| Priority date | — |
| Expiry date | Sep 3, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/158
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of determining a patient's HPD status comprising the steps of a) examining a patient tumor sample for the expression level of HPD-diagnostic biomarkers, and b) determining whether the signature of the biomarkers is similar to that of a HPD positive signature is disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.